{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:04:49Z","timestamp":1764687889703,"version":"3.44.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bulcan.2020.07.008","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T17:48:57Z","timestamp":1600969737000},"page":"187-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["LAL chez l\u2019adulte\u00a0: apport et limite de la prise en charge p\u00e9diatrique"],"prefix":"10.1016","volume":"108","author":[{"given":"Florence","family":"Rabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2020.07.008_bib0250","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0255","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0260","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1\u00a0and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0265","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0270","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0280","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0285","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2011.141","article-title":"Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40","volume":"25","author":"Rijneveld","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0290","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0295","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3561.3561","article-title":"Dose-intensity impacts on survival of adolescents and young adults with acute lymphoblastic leukemia treated in adult departments by a pediatric protocol (FRALLE 2000BT)","volume":"120","author":"Cluzeau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0300","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0305","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0310","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350\u00a0years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0315","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin\u2013Frankfurt\u2013M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0320","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0325","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.762.762","article-title":"The upper age limit for a pediatric-inspired therapy in younger adults with Ph-negative acute lymphoblastic leukemia (ALL)? Analysis of the GRAALL-2005\u00a0study","volume":"128","author":"Huguet","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0335","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008\u00a0treatment for patients aged 1\u201345\u00a0years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0340","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003\u00a0study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clml.2016.11.002","article-title":"Hyper-CVAD compared with BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. a retrospective single-center analysis","volume":"17","author":"El-Cheikh","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0350","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u00a0\u2013\u00a0Childhood Leukemia Cooperative Group","volume":"339","author":"Cav\u00e9","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0355","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0360","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0365","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005\u00a0clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.552.552","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in adults with philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): results from the group for research on adult AlL (GRAALL)","volume":"122","author":"Dhedin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0375","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0380","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1493.1493","volume":"120","author":"Goekbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0385","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96\u00a0trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0390","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3962.3962","article-title":"Outcome of patients age 60\u00a0and over with acute lymphoblastic leukemia (ALL) treated with a modified pediatric protocol","volume":"112","author":"Kao","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0395","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","article-title":"Improved prognosis for older adolescents with acute lymphoblastic leukemia","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0400","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beha.2008.08.004","article-title":"Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?","volume":"21","author":"Douer","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0405","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14\u00a0trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0410","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0415","article-title":"Tolerance, compliance and efficacy of L-asparaginase during induction phase in adult philadelphia-negative acute lymphoblastic leukemia: experience of the GRAALL-2005","volume":"101","author":"Balsat","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0420","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0425","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55\u00a0years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0430","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.80.80","article-title":"A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial","volume":"126","author":"DeAngelo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0435","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0440","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","article-title":"A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904\u00a0study","volume":"101","author":"Chiaretti","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0445","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128759","article-title":"Dasatinib-blinatumomab combination for the front-line treatment of adult Ph+ ALL patients. Updated results of the gimema LAL2116\u00a0D-alba trial","volume":"134","author":"Chiaretti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0450","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2\u00a0study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0455","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.98.98","article-title":"CA180-372: an international collaborative phase 2\u00a0trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"130","author":"Hunger","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0460","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0465","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0470","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2\u00a0study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0475","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0480","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0485","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.008_bib0490","first-page":"372","article-title":"Mechanisms of resistance to CAR-T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120303520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120303520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:05Z","timestamp":1757792045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120303520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0007455120303520"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.07.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LAL chez l\u2019adulte\u00a0: apport et limite de la prise en charge p\u00e9diatrique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}